David Reeves, MD
Pulmonary Disease · Dover, NHNPI 1992884837
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.8% of the total across 35 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by GSK at 29.5% of the total. Reporting peaked in 2019 at $337 and has fallen 92.5% since, to $25 in 2025.
Across 35 payments — averaging $18.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$196
- Actelion Pharmaceuticals US, Inc.$128
- AstraZeneca$95
- Harmony Biosciences LLC$66
- Mylan Specialty L.p.$53
- Takeda Pharmaceuticals U.S.A., Inc.$39
- plus $85 from 4 others
What the payments were for
- Food & beverage$64197%
- Education$213%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 10 | $196 |
| Actelion Pharmaceuticals US, Inc. | 7 | $128 |
| AstraZeneca | 6 | $95 |
| Harmony Biosciences LLC | 3 | $66 |
| Mylan Specialty L.p. | 3 | $53 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $39 |
| Regeneron Healthcare Solutions, Inc. | 1 | $24 |
| Sanofi | 1 | $24 |
| United Therapeutics Corporation | 1 | $21 |
| Shire North American Group Inc | 1 | $17 |
How this compares
$662 in reported general payments places this provider in the 65th percentile of 78 pulmonary disease providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 96 | $111,055 |
| Breo ElliptaFluticasone/Vilanterol | 96 | $46,331 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 41 | $26,039 |
| Spiriva RespimatTiotropium Bromide | 28 | $17,465 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 33 | $15,254 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 19 | $12,072 |
| Incruse ElliptaUmeclidinium Bromide | 25 | $9,496 |
| SymbicortBudesonide/Formoterol Fumarate | 26 | $7,065 |
| Advair DiskusFluticasone Propion/Salmeterol | 24 | $4,355 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 124 | $3,426 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 37 | $3,038 |
| Montelukast Sodium | 21 | $829 |
| Roflumilast | 25 | $509 |
| Prednisone | 20 | $45 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $196 | $182,135250 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $95 | $19,13745 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 78 pulmonary disease providers in New Hampshire.
Other pulmonary disease in Dover
- Bianca MonteiroDover$43K
- Yuttiwat VorakunthadaDover$2K
- Vinia Madonna MendozaDover$594
- Dhruv DesaiDover$138
- Syed Mudassar NaqshbandiDover$59
- Manuel de AguirreDover$31
- Donald MahlerLebanon$411K
- Jeffrey StewartLebanon$30K
- Erik SwensonLebanon$29K
- Elliot BackerLebanon$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.